Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Evinova will operate as a separate health-tech business within AstraZeneca
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
The company has raised US$4.5 million in funding for its AI operating system
European operations' revenue grew 58.4% to Rs 599.7 crore
The companies plan to start a pivotal Phase 3 trial in the coming months
Subscribe To Our Newsletter & Stay Updated